AstraZeneca PLC (AZNCF)
OTCMKTS
· Delayed Price · Currency is USD
135.36
0.00 (0.00%)
May 13, 2025, 4:00 PM EDT
AstraZeneca Revenue
AstraZeneca had revenue of $13.59B in the quarter ending March 31, 2025, with 7.17% growth. This brings the company's revenue in the last twelve months to $54.98B, up 15.48% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
54.98B
Revenue Growth
+15.48%
P/S Ratio
3.81
Revenue / Employee
583.05K
Employees
94,300
Market Cap
209.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
AstraZeneca News
- 4 hours ago - P/E Ratio Insights for AstraZeneca - Benzinga
- 7 hours ago - BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma - Accesswire
- 1 day ago - AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025 - Business Wire
- 2 days ago - AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER - This is Money
- 2 days ago - Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices - WSJ
- 2 days ago - Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%' - The Guardian
- 2 days ago - AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News - GuruFocus
- 5 days ago - AstraZeneca's bladder cancer treatment shows positive results in trial - Seeking Alpha